ArticleRSC medicinal chemistry2022

Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.

Ferah Comert Onder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.